Loading...

WOCKPHARMA Wockhardt Ltd Product Launches Announcement

Wckh

WCKP

Wockhardt Ltd

(WOCKPHARMA)

2025 Announcement

Show Summary

Summary

Special Share Lodgement

Medical Journal Publication

AGM Announcement

Compliance Certificate

Strategic Realignment

Earnings Call Transcript

Investor Presentation

Investor Presentation

Financial Results

Management Changes

Annual Compliance Report

Monitoring Agency Report

Compliance Certificate

New Subsidiary Formed

Successful Treatment

Share Allotment

Funds Utilization Update

Monitoring Agency Report

Q3 Financial Results

New Antibiotic Success

Compliance Certificate

New Drug Efficacy

New Antibiotic Approval

Successful Liver Transplant

No Fund Deviation

QIP Utilization Report

Financial Results Q2

Equity Shares Allotment

Investor Meeting

Investor Meeting

Investor Presentation

Volume Movement Clarified

Compliance Certificate

New Antibiotic Launch

Management Change

Lifetime Achievement Award

New Drug Success

New Drug Success

Innovator Award Received

Regulatory Fines Imposed

Allegations Denied

Redemption of Debenture

Earnings Results

Funds Utilization Confirmation

Monitoring Agency Report

Financial Results & Appoint...

Compliance Certificate Subm...

Management Change

WOCKHARDT LTD. Press Release

Successful Use of Antibiotic

Management Change

Appointment of Auditors

Financial Update

Antibiotic trial update

Annual Compliance Report Su...

Credit Rating Announcement

Funds Utilization Confirmation

Monitoring Report

Credit rating change by ICR...

Certificate Issuance

Compliance Certificate Rece...

Compliance Certificate

Tenure Completion

Allotment of Equity Shares

Clinical Success Announcement

Investor Presentation

Financial Results

Revised Outcome Submission

Allotment of ESOP/ESPS

Certificate Submission

IEPF Share Transfer

Phase 3 Pneumonia Study

Financial Results

Equity Allotment

Compliance Certificate Subm...

Credit Rating Revision

Financial Statements

Voluntary Delisting

Equity Offerings

Layoffs, Labor disputes

Financial Statements, Earni...

Financial Statements

Credit Downgrade

Related party transactions

Financial Results Announcement

Regulatory Compliance

Investor Meetings

External Links:

Data:

Wockhardt's novel antibiotic Zaynich (Zidebactam/Cefepime), in a Phase III study, achieved a 96.8% clinical cure rate for complicated urinary infections, attracting global interest for compassionate use.

AI Assistant

Wockhardt Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.